¼¼°èÀÇ °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : Á¦Ç° À¯Çü, ±â¼ú, ¿ëµµ, À¯Åë ä³Î, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)
Transdermal Patches Market by Product, Type, Technology, Application, Distribution Channel, End Users - Global Forecast 2025-2030
°æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀº 2023³â¿¡ 85¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 98¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 16.40%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 248¾ï 4,000¸¸ ´Þ·¯°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°æÇÇ Èí¼ö ÆÐÄ¡´Â ÇǺηκÎÅÍ ¾à¹°À» Àü´ÞÇÏ´Â Á¢Âø ÆÐÄ¡À̸ç, Àå±â°£¿¡ °ÉÃÄ Ç÷·ù·ÎÀÇ ¾ÈÁ¤ÀûÀÎ Á¦¾î ¹æÃâÀ» º¸ÀåÇÕ´Ï´Ù. ºñħ½À¼º, ȯÀÚÀÇ ÄÄÇöóÀ̾𽺠Çâ»ó, ¼Òȱâ°è¸¦ ¿ìȸÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ »ïŰ´Â °ï¶õÇÑ È¯ÀÚ³ª ƯÁ¤ Åõ¾àÀÌ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô ÀûÇÕÇϱ⠶§¹®¿¡ ÇʼöÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ½À´Ï´Ù. ÅëÁõ °ü¸®, ´ÏÄÚÆ¾ ÀÌÅ»ºÎÅÍ È£¸£¸ó º¸Ãæ ¿ä¹ý ¹× ¸¸¼º Áúȯ Ä¡·á¿¡ À̸£´Â Ä¡·á ¹üÀ§´Â ´Ù¾çÇÕ´Ï´Ù. ÃÖÁ¾ ¿ëµµ¿¡´Â ÁÖ·Î ÀÇ·á ½Ã¼³, Ŭ¸®´Ð ¹× ÀçÅÃÄ¡·á ȯ°æÀÌ Æ÷ÇԵ˴ϴÙ. °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ¸¸¼º Áúȯ Áõ°¡, °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Ã¤¿ë Áõ°¡, ÆÐÄ¡ ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ´Â º¹¿ë·® ¸ð´ÏÅ͸µ ¼¾¼¿Í °°Àº ½º¸¶Æ® ±â¼úÀÇ ÅëÇÕ°ú ƯÁ¤ ȯÀÚÀÇ ¿ä±¸¸¦ ¸ñÇ¥·Î ÇÑ °³ÀÎÈµÈ ÀÇ·á Á¢±Ù¹ý¿¡ ÀÖ½À´Ï´Ù. ±â¾÷Àº ¾à¹°À» Àü´ÞÇÏ´Â °Í»Ó¸¸ ¾Æ´Ï¶ó »ýü ½ÅÈ£¸¦ ¸ð´ÏÅ͸µÇÏ´Â ÆÐÄ¡¿Í °°Àº ´Ù±â´É ÆÐÄ¡¸¦ °³¹ßÇϱâÀ§ÇÑ ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇÔÀ¸·Î½á ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÇѰè·Î´Â ÇǺΠÀڱؼº ¹®Á¦, ƯÁ¤ ¾à¹°¿¡ ´ëÇÑ Á¦ÇÑÀûÀÎ Åõ°ú¼º, ȯÀÚ¿¡ ÀÇÇÑ ÇǺΠÈí¼öÀÇ ÆíÂ÷ µîÀÌ ÀÖ¾î È¿´É¿¡ ´ëÇÑ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î °æÇÇ Èí¼ö ½Ã½ºÅÛÀÇ ±ÔÁ¦ ½ÂÀÎÀº ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ¾ö°ÝÇÏ°Ô Á¦Ç° ½ÃÀåÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº Ä¡¿Çϸç ÁÖ¿ä ±â¾÷µéÀº Æ÷Æ®Æú¸®¿À È®´ë¿Í Áö¸®Àû Á¸Àç¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.Çõ½ÅÀÇ ±âȸ´Â ÆÐÄ¡ÀÇ Á¡Âø¼ºÀ» Çâ»ó½Ã۰í ÇǺΠ¹ÝÀÀÀ» ÃÖ¼ÒÈÇÏ´Â »ýü ÀûÇÕ¼º ¼ÒÀç¿Í ÇöÀç ¾ÆÁ÷ ÃæºÐÈ÷ º¸±ÞµÇÁö ¾ÊÀº »ý¹° Á¦Á¦ÀÇ °æÇÇ Àü´Þ ¿É¼ÇÀÇ °³¹ß¿¡ Á¸ÀçÇÕ´Ï´Ù. º¸´Ù Á¾ÇÕÀûÀÎ ¾à¹° Àü´Þ ¹æ¹ýÀ» À§ÇØ °æÇÇ Èí¼ö ÆÐÄ¡¿Í ÁÖ»çÁ¦ ¼ººÐÀ» °áÇÕÇÑ ÇÏÀ̺긮µå ½Ã½ºÅÛÀ¸·ÎÀÇ ½ÃÇÁÆ®¸¦ º¼ ¼ö ÀÖ½À´Ï´Ù. ¼ºÀå°ú °æÀï ¿ìÀ§¸¦ À§Çؼ´Â Áö¼ÓÀûÀÎ Çõ½Å°ú ÀûÀÀÀÌ ÇʼöÀûÀÔ´Ï´Ù.
ÁÖ¿ä ½ÃÀå Åë°è |
±âÁسâ(2023) |
85¾ï 7,000¸¸ ´Þ·¯ |
¿¹Ãø³â(2024) |
98¾ï 9,000¸¸ ´Þ·¯ |
¿¹Ãø³â(2030) |
248¾ï 4,000¸¸ ´Þ·¯ |
CAGR(%) |
16.40% |
½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈÇÏ´Â °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³
°æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. Á¤±³È ¹× »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ ¼¼°è Áõ°¡
- ¾à¹° ¹æÃâ Á¦¾î ¹× ºñħ½À ¾à¹° Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
- °æÇÇÈí¼öÆÐÄ¡ÀÇ Á¤ºÎÇã°¡¼ö Áõ°¡
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- °æÇÇ Èí¼ö ÆÐÄ¡¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë
- ½ÃÀå ±âȸ
- °íµµ·Î È¿À²ÀûÀÎ °æÇÇ ¾à¹° Àü´Þ ÆÐÄ¡ÀÇ ¿¬±¸ °³¹ß ÁøÇà
- °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ Á¦Á¦È¿Í Á¦Á¶¿¡ ÀÖ¾î¼ÀÇ »õ·Î¿î Áøº¸
- ½ÃÀåÀÇ °úÁ¦
- Á¦Ç° ¸®ÄÝ¿¡ ¼ö¹ÝÇÏ´Â °æÇÇ Èí¼öÇü Á¦Á¦ÀÇ ÇѰè
Porter's Five Force : °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸
Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °ÀÎÇÑ ½ÃÀå¿¡¼ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.
PESTLE ºÐ¼® : °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå¿¡¼ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç
¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.
½ÃÀå Á¡À¯À² ºÐ¼® : °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç
°æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå¿¡¼ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡
FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå¿¡¼ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
ÀÌ º¸°í¼´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.
2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.
3. ½ÃÀå ´Ù¾çÈ: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.
4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.
5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °Á¶ÇÕ´Ï´Ù.
¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.
1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?
2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?
3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?
4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?
5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ½ÃÀå °³¿ä
Á¦5Àå ½ÃÀå ÀλçÀÌÆ®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼¼°è¿¡¼ ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡ °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ »ç¿ëÀÌ Áõ°¡
- Á¦¾îµÈ ¾à¹° ¹æÃâ°ú ºñħ½ÀÀûÀÎ ¾à¹° Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½É Áõ°¡
- °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ Á¤ºÎ ½ÂÀÎ ¼ö Áõ°¡
- ¾ïÁ¦¿äÀÎ
- °æÇÇ Èí¼ö ÆÐÄ¡¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë
- ±âȸ
- ÷´Ü °íÈ¿À² °æÇÇ ¾à¹° Àü´Þ ÆÐÄ¡ÀÇ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß
- °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ Ã³¹æ°ú Á¦Á¶¿¡ ÀÖ¾î¼ÀÇ »õ·Î¿î Áøº¸
- °úÁ¦
- °æÇÇ Èí¼öÇü ÀǾàǰÀÇ Á¦ÇѰú Á¦Ç° ¸®ÄÝ
- ½ÃÀå ¼¼ºÐÈ ºÐ¼®
- Á¦Ç°: ´ÙÃþ ¾àÁ¦ Á¢Âø ÆÐÄ¡ÀÇ ÇöÀúÇÑ Ä§Åõ
- À¯Çü : ´ÏÄÚÆ¾ÀÇ ±¤¹üÀ§ÇÑ ¿ä±¸ »çÇ× °æÇÇ Èí¼ö ÆÐÄ¡
- ±â¼ú: °æÇÇ ÆÐÄ¡ÀÇ È¿´ÉÀ» ³ôÀÌ´Â ÈÇÐ Áõ°Á¦ÀÇ ÀÌ¿ë
- ¿ëµµ : È£¸£¸ó ¿ä¹ý¿¡¼ °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ ÀÌ¿ë È®´ë
- À¯Åë ä³Î : ÀüÀÚ»ó°Å·¡ Ç÷§Æû¿¡¼ÀÇ °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ º¸±Þ
- ÃÖÁ¾ »ç¿ëÀÚ : º´¿ø¿¡¼ °æÇÇ Èí¼ö ÆÐÄ¡ÀÇ Ã³¹æ Áõ°¡
- Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- Á¤Ä¡Àû
- °æÁ¦
- »ç±³
- ±â¼úÀû
- ¹ý·ü»ó
- ȯ°æ
Á¦6Àå °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : Á¦Ç°º°
- ¸ÅÆ®¸¯½º
- ´ÙÃþ ¾àÁ¦³» Á¢ÂøÁ¦
- Àú¼öÁö
- ´ÜÃþ ¾àÁ¦ ÇÔÀ¯ Á¢ÂøÁ¦
Á¦7Àå °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : À¯Çüº°
- ºÎÇÁ·¹³ë¸£ÇÉ °æÇÇ ÆÐÄ¡
- Å©·Î´Ïµò °æÇÇ ÆÐÄ¡
- ÆæÅ¸´Ò °æÇÇ ÆÐÄ¡
- ´ÏÄÚÆ¾ °æÇÇ ÆÐÄ¡
- ¿Á½ÃºÎƼ´Ñ °æÇÇ ÆÐÄ¡
Á¦8Àå °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : ±â¼úº°
- ÈÇÐ °ÈÁ¦
- Àü·ù
- ±â°è ¾î·¹ÀÌ
- ¿ ÀýÁ¦
Á¦9Àå °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : ¿ëµµº°
- È£¸£¸ó ¿ä¹ý
- °úȰµ¿ ¹æ±¤
- ÅëÁõ ¿ÏÈ
- Èí¿¬ °¨¼Ò¿Í ±Ý¿¬ Áö¿ø
Á¦10Àå °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : À¯Åë ä³Îº°
Á¦11Àå °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°
- Ŭ¸®´Ð
- °¡Á¤Ä¡·á ȯ°æ
- º´¿ø
Á¦12Àå ¾Æ¸Þ¸®Ä«ÀÇ °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå
- ¾Æ¸£ÇîÆ¼³ª
- ºê¶óÁú
- ij³ª´Ù
- ¸ß½ÃÄÚ
- ¹Ì±¹
Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾ç °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå
- È£ÁÖ
- Áß±¹
- Àεµ
- Àεµ³×½Ã¾Æ
- ÀϺ»
- ¸»·¹À̽þÆ
- Çʸ®ÇÉ
- ½Ì°¡Æ÷¸£
- Çѱ¹
- ´ë¸¸
- ű¹
- º£Æ®³²
Á¦14Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °æÇÇ Èí¼ö ÆÐÄ¡ ½ÃÀå
- µ§¸¶Å©
- ÀÌÁýÆ®
- Çɶõµå
- ÇÁ¶û½º
- µ¶ÀÏ
- À̽º¶ó¿¤
- ÀÌÅ»¸®¾Æ
- ³×´ú¶õµå
- ³ªÀÌÁö¸®¾Æ
- ³ë¸£¿þÀÌ
- Æú¶õµå
- īŸ¸£
- ·¯½Ã¾Æ
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«
- ½ºÆäÀÎ
- ½º¿þµ§
- ½ºÀ§½º
- ÅÍŰ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- ¿µ±¹
Á¦15Àå °æÀï ±¸µµ
- ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
- FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
- °æÀï ½Ã³ª¸®¿À ºÐ¼®
- DifGen Pharmaceuticals´Â ¹Ì±¹ÀÇ Á¦Á¶ °ÅÁ¡ Aveva ¾à¹°Àü´Þ Systems¿¡¼ µÎ ¹øÂ° Á¦Ç°ÀÎ ºÎÇÁ·¹³ë¸£ÇÉ °æÇÇ Èí¼ö ½Ã½ºÅÛÀ» Ãâ½ÃÇÕ´Ï´Ù.
- Luye Pharma Ltd°¡ ¿µ±¹¿¡¼ »õ·Î¿î ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·á¸¦ ¹ß¸Å
- Corsair Pharma, Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõÀÇ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϱâ À§ÇØ 2,300¸¸ ´Þ·¯ÀÇ ½Ã¸®Áî B ÀÚ±Ý Á¶´ÞÀ» ¹ßÇ¥
- Vaxess, mRNA ¹é½Å ÆÐÄ¡ °³¹ß °¡¼ÓÀ» À§ÇØ 900¸¸ ´Þ·¯¸¦ Á¶´Þ
- ¾Ë·ç¹Ì´½, ½ºÆäÀο¡¼ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÀÇ ÆÇ¸Å±ÇÀ» 4,500¸¸ À¯·Î·Î Ãëµæ
- Corium°ú Lotus Pharmaceutical, Çõ½ÅÀûÀÎ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·á ¡¸ADLARITY¡¹ÀÇ ¾Æ½Ã¾Æ º¹¼ö ½ÃÀå¿¡¼ÀÇ µ¶Á¡ ¶óÀ̼±½º °è¾àÀ» ü°á
- µ¦½º¸Þµ¥Åä¹Ìµò °æÇÇ ÆÐÄ¡°¡ ¼ö¼ú ÈÄ ÅëÁõ °ü¸®¿¡ ±ÞÈ÷ ½ÂÀÎ
- LTS, SorrelÀÇ ¿þ¾î·¯ºí ÁÖ»ç µð¹ÙÀ̽º »ç¾÷ÀÇ Àμö¿¡ ÀÇÇØ °íºÐÀÚ ¾à¹°Àü´Þ¿¡ÀÇ Âü°¡¸¦ ¿Ï·á
- BioNxt, ÆÄŲ½¼º´ Ä¡·áÁ¦ ·ÎƼ°íƾ °æÇÇ ÆÐÄ¡ÀÇ À¯·´ ÀÓ»ó½ÃÇèÀÇ ½ÂÀÎÀ» Ãëµæ
- Bionxt, ÆÄŲ½¼º´ Ä¡·áÁ¦ ·ÎƼ°íƾ °æÇÇ ÆÐÄ¡ÀÇ ÀÓ»ó½ÃÇè °è¾àÀ» ü°áÇϰí, ÀÓ»ó »ùÇÃÀÇ Á¦Á¶¸¦ °³½Ã
- LTS LohmannÀÌ ¹«Ä§ Ãâ»ê Àü¹®±â¾÷ ÅõÀÚ¸¦ ÁÖµµ
- Tesa Labtec GmbHÀÇ Àμö´Â AdhexPharmaÀÇ ¼ºÀåÀÇ ±âÃʰ¡ µÈ´Ù
±â¾÷ ¸ñ·Ï
- Novartis AG
- Luye Pharma Group Ltd
- Gedeon Richter Plc
- Johnson & Johnson Services, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- DifGen Pharmaceuticals LLC
- Zydus Group
- Bliss GVS Pharma Ltd.
- Sparsha Pharma International Pvt Ltd
- GlaxoSmithKline Plc
- LAVIPHARM GROUP HOLDING SA
- Purdue Pharma LP
- Nitto Denko Corporation
- UCB SA
- Corsair Pharma, Inc.
- Amneal Pharmaceuticals, Inc.
- Tesa SE by Beiersdorf AG
- Medherant Limited
- ALVOGEN
- AdhexPharma SAS
- Tapemark by LTS Lohmann Therapie-Systeme AG
- Icure Pharmaceutical Inc.
- ProSolus, Inc.
- Corium, Inc.
- Viatris Inc.
- Boehringer Ingelheim International GmbH
- Endo International plc
- BioNxt Solutions Inc.
- Bayer AG
- Nutriband Inc
- Teikoku Seiyaku Co., Ltd.
- Perrigo Company plc
- Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc.
JHS
The Transdermal Patches Market was valued at USD 8.57 billion in 2023, expected to reach USD 9.89 billion in 2024, and is projected to grow at a CAGR of 16.40%, to USD 24.84 billion by 2030.
Transdermal patches are adhesive patches that deliver medication through the skin, ensuring steady and controlled release into the bloodstream over time. They are essential due to their non-invasive nature, improved patient compliance, and ability to bypass the gastrointestinal system, which makes them suitable for patients with swallowing difficulties or specific medication requirements. Applications span from pain management and nicotine withdrawal to hormone replacement therapy and chronic disease treatment. The end-use scope primarily includes healthcare facilities, clinics, and home healthcare settings. Growth in the transdermal patch market is primarily driven by rising chronic disease prevalence, increasing adoption of transdermal drug delivery systems, and advancements in patch technology. Emerging opportunities lie in the integration of smart technologies like sensors for dosage monitoring and personalized medicine approaches targeting specific patient needs. Companies might benefit from investing in R&D for developing patches with multifunctional capabilities, such as patches that not only deliver medication but also monitor vital signs. Limitations include skin irritation issues, limited permeability to certain drugs, and variability in skin absorption among patients, which pose challenges to efficacy. Furthermore, regulatory approval for new transdermal systems is stringent due to safety concerns, potentially slowing down product launches. The market is highly competitive, with key players focusing on expanding portfolios and geographical presence. Innovation opportunities exist in biocompatible materials to improve patch adhesion and minimize skin reactions, and developing transdermal delivery options for biologics, which are currently underrepresented. Trends show a shift towards hybrid systems that combine transdermal patches with injectable components for a more comprehensive drug delivery method. The market's nature is dynamic, driven by technological advancements and evolving consumer preferences, making ongoing innovation and adaptation crucial for sustained growth and competitive advantage in the transdermal patch industry.
KEY MARKET STATISTICS |
Base Year [2023] |
USD 8.57 billion |
Estimated Year [2024] |
USD 9.89 billion |
Forecast Year [2030] |
USD 24.84 billion |
CAGR (%) |
16.40% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Transdermal Patches Market
The Transdermal Patches Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Increased use of transdermal patches to treat chronic conditions worldwide
- Rising preference for controlled drug release and non-invasive drug delivery solutions
- Growing number of government approvals for transdermal patches
- Market Restraints
- High costs associated with transdermal patches
- Market Opportunities
- Ongoing research and development for advanced and highly efficient transdermal drug delivery patches
- Emerging advances in the formulation and manufacturing of transdermal patches
- Market Challenges
- Limitations associated with transdermal drugs along with product recalls
Porter's Five Forces: A Strategic Tool for Navigating the Transdermal Patches Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Transdermal Patches Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Transdermal Patches Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Transdermal Patches Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Transdermal Patches Market
A detailed market share analysis in the Transdermal Patches Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Transdermal Patches Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Transdermal Patches Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Key Company Profiles
The report delves into recent significant developments in the Transdermal Patches Market, highlighting leading vendors and their innovative profiles. These include Novartis AG, Luye Pharma Group Ltd, Gedeon Richter Plc, Johnson & Johnson Services, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., DifGen Pharmaceuticals LLC, Zydus Group, Bliss GVS Pharma Ltd., Sparsha Pharma International Pvt Ltd, GlaxoSmithKline Plc, LAVIPHARM GROUP HOLDING S.A., Purdue Pharma L.P., Nitto Denko Corporation, UCB S.A., Corsair Pharma, Inc., Amneal Pharmaceuticals, Inc., Tesa SE by Beiersdorf AG, Medherant Limited, ALVOGEN, AdhexPharma SAS, Tapemark by LTS Lohmann Therapie-Systeme AG, Icure Pharmaceutical Inc., ProSolus, Inc., Corium, Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Endo International plc, BioNxt Solutions Inc., Bayer AG, Nutriband Inc, Teikoku Seiyaku Co., Ltd., Perrigo Company plc, and Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc..
Market Segmentation & Coverage
This research report categorizes the Transdermal Patches Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Product, market is studied across Matrix, Multi-layer Drug-in-Adhesive, Reservoir, and Single-layer Drug-in-Adhesive.
- Based on Type, market is studied across Buprenorphine Transdermal Patch, Clonidine Transdermal Patch, Fentanyl Transdermal Patch, Nicotine Transdermal Patch, and Oxybutynin Transdermal Patch.
- Based on Technology, market is studied across Chemical Enhancers, Electric Current, Mechanical Arrays, and Thermal Ablation.
- Based on Application, market is studied across Hormonal Therapy, Overactive Bladder, Pain Relief, and Smoking Reduction & Cessation Aid.
- Based on Distribution Channel, market is studied across Offline and Online.
- Based on End Users, market is studied across Clinics, Home Care Settings, and Hospitals.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increased use of transdermal patches to treat chronic conditions worldwide
- 5.1.1.2. Rising preference for controlled drug release and non-invasive drug delivery solutions
- 5.1.1.3. Growing number of government approvals for transdermal patches
- 5.1.2. Restraints
- 5.1.2.1. High costs associated with transdermal patches
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing research and development for advanced and highly efficient transdermal drug delivery patches
- 5.1.3.2. Emerging advances in the formulation and manufacturing of transdermal patches
- 5.1.4. Challenges
- 5.1.4.1. Limitations associated with transdermal drugs along with product recalls
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Significant penetration of Multi-layer Drug-in-Adhesive patches
- 5.2.2. Type: Extensive requirement for nicotine transdermal patches
- 5.2.3. Technology: Utilization of chemical enhancers to improve transdermal patch efficacy
- 5.2.4. Application: Expanding use of transdermal patches for hormonal therapy
- 5.2.5. Distribution Channel: Proliferation of transdermal patches on eCommerce platforms
- 5.2.6. End Users: Increasing prescription of transdermal patches in hospitals
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Transdermal Patches Market, by Product
- 6.1. Introduction
- 6.2. Matrix
- 6.3. Multi-layer Drug-in-Adhesive
- 6.4. Reservoir
- 6.5. Single-layer Drug-in-Adhesive
7. Transdermal Patches Market, by Type
- 7.1. Introduction
- 7.2. Buprenorphine Transdermal Patch
- 7.3. Clonidine Transdermal Patch
- 7.4. Fentanyl Transdermal Patch
- 7.5. Nicotine Transdermal Patch
- 7.6. Oxybutynin Transdermal Patch
8. Transdermal Patches Market, by Technology
- 8.1. Introduction
- 8.2. Chemical Enhancers
- 8.3. Electric Current
- 8.4. Mechanical Arrays
- 8.5. Thermal Ablation
9. Transdermal Patches Market, by Application
- 9.1. Introduction
- 9.2. Hormonal Therapy
- 9.3. Overactive Bladder
- 9.4. Pain Relief
- 9.5. Smoking Reduction & Cessation Aid
10. Transdermal Patches Market, by Distribution Channel
- 10.1. Introduction
- 10.2. Offline
- 10.3. Online
11. Transdermal Patches Market, by End Users
- 11.1. Introduction
- 11.2. Clinics
- 11.3. Home Care Settings
- 11.4. Hospitals
12. Americas Transdermal Patches Market
- 12.1. Introduction
- 12.2. Argentina
- 12.3. Brazil
- 12.4. Canada
- 12.5. Mexico
- 12.6. United States
13. Asia-Pacific Transdermal Patches Market
- 13.1. Introduction
- 13.2. Australia
- 13.3. China
- 13.4. India
- 13.5. Indonesia
- 13.6. Japan
- 13.7. Malaysia
- 13.8. Philippines
- 13.9. Singapore
- 13.10. South Korea
- 13.11. Taiwan
- 13.12. Thailand
- 13.13. Vietnam
14. Europe, Middle East & Africa Transdermal Patches Market
- 14.1. Introduction
- 14.2. Denmark
- 14.3. Egypt
- 14.4. Finland
- 14.5. France
- 14.6. Germany
- 14.7. Israel
- 14.8. Italy
- 14.9. Netherlands
- 14.10. Nigeria
- 14.11. Norway
- 14.12. Poland
- 14.13. Qatar
- 14.14. Russia
- 14.15. Saudi Arabia
- 14.16. South Africa
- 14.17. Spain
- 14.18. Sweden
- 14.19. Switzerland
- 14.20. Turkey
- 14.21. United Arab Emirates
- 14.22. United Kingdom
15. Competitive Landscape
- 15.1. Market Share Analysis, 2023
- 15.2. FPNV Positioning Matrix, 2023
- 15.3. Competitive Scenario Analysis
- 15.3.1. DifGen Pharmaceuticals Launches A Second Product - Buprenorphine Transdermal System From Its U.S. Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing U.S. Made Transdermal Patches And Sublingual Films
- 15.3.2. Luye Pharma Ltd Launches New Alzheimer's Treatment In The UK
- 15.3.3. Corsair Pharma Announces USD 23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
- 15.3.4. Vaxess Raises USD 9 Million to Accelerate mRNA Vaccine Patch Development
- 15.3.5. Almirall Acquires Rights To Distribute Alzheimer's Treatment In Spain For An Initial EUR 45 Million
- 15.3.6. Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY in Multiple Markets Across Asia
- 15.3.7. Dexmedetomidine Transdermal Patch Fast Tracked for Postop Pain Management
- 15.3.8. LTS Completes its Entry into Large Molecule Drug Delivery with the Acquisition of the Sorrel Wearable Injection Device Business
- 15.3.9. BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease
- 15.3.10. Bionxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson's Disease
- 15.3.11. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
- 15.3.12. The Addition of Tesa Labtec GmbH Marks a Cornerstone in AdhexPharma's Growth Path
Companies Mentioned
- 1. Novartis AG
- 2. Luye Pharma Group Ltd
- 3. Gedeon Richter Plc
- 4. Johnson & Johnson Services, Inc.
- 5. AbbVie Inc.
- 6. Teva Pharmaceutical Industries Ltd.
- 7. DifGen Pharmaceuticals LLC
- 8. Zydus Group
- 9. Bliss GVS Pharma Ltd.
- 10. Sparsha Pharma International Pvt Ltd
- 11. GlaxoSmithKline Plc
- 12. LAVIPHARM GROUP HOLDING S.A.
- 13. Purdue Pharma L.P.
- 14. Nitto Denko Corporation
- 15. UCB S.A.
- 16. Corsair Pharma, Inc.
- 17. Amneal Pharmaceuticals, Inc.
- 18. Tesa SE by Beiersdorf AG
- 19. Medherant Limited
- 20. ALVOGEN
- 21. AdhexPharma SAS
- 22. Tapemark by LTS Lohmann Therapie-Systeme AG
- 23. Icure Pharmaceutical Inc.
- 24. ProSolus, Inc.
- 25. Corium, Inc.
- 26. Viatris Inc.
- 27. Boehringer Ingelheim International GmbH
- 28. Endo International plc
- 29. BioNxt Solutions Inc.
- 30. Bayer AG
- 31. Nutriband Inc
- 32. Teikoku Seiyaku Co., Ltd.
- 33. Perrigo Company plc
- 34. Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc.